CL2007002878A1 - Agente farmaceutico que comprende 1) un inhibidor de her2 que tiene un esqueleto de pirrolopirimidina o de pirazolopirimidina y 2) un agente terapeutico hormonal o anticancerigeno en combinacion; y uso pra la prevencion o el tratamiento del cancer. - Google Patents

Agente farmaceutico que comprende 1) un inhibidor de her2 que tiene un esqueleto de pirrolopirimidina o de pirazolopirimidina y 2) un agente terapeutico hormonal o anticancerigeno en combinacion; y uso pra la prevencion o el tratamiento del cancer.

Info

Publication number: CL2007002878A1
Authority: CL; Chile
Prior art keywords: pirrolopirimidine; pirazolopirimidine; hormonal; skeleton; bank
Prior art date: 2006-10-06

Application number

CL200702878A

Other languages

English (en)

Inventor

Ohta Toshiya Tamura Yoshikazu

Original Assignee

Takeda Pharmaceutical

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-10-06

Filing date

2007-10-05

Publication date

2008-08-01

2007-10-05 Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical

2008-08-01 Publication of CL2007002878A1 publication Critical patent/CL2007002878A1/es

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Microbiology (AREA)
Mycology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

CL200702878A 2006-10-06 2007-10-05 Agente farmaceutico que comprende 1) un inhibidor de her2 que tiene un esqueleto de pirrolopirimidina o de pirazolopirimidina y 2) un agente terapeutico hormonal o anticancerigeno en combinacion; y uso pra la prevencion o el tratamiento del cancer. CL2007002878A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2006275841		2006-10-06
JP2007057902		2007-03-07

Publications (1)

Publication Number	Publication Date
CL2007002878A1 true CL2007002878A1 (es)	2008-08-01

Family

ID=39283276

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL200702878A CL2007002878A1 (es)	2006-10-06	2007-10-05	Agente farmaceutico que comprende 1) un inhibidor de her2 que tiene un esqueleto de pirrolopirimidina o de pirazolopirimidina y 2) un agente terapeutico hormonal o anticancerigeno en combinacion; y uso pra la prevencion o el tratamiento del cancer.

Country Status (23)

Country	Link
US (1)	US20100008912A1 (es)
EP (2)	EP2359825A2 (es)
JP (1)	JP2010505745A (es)
KR (1)	KR20090094804A (es)
CN (1)	CN101553222A (es)
AR (1)	AR063152A1 (es)
AU (1)	AU2007307489A1 (es)
BR (1)	BRPI0717477A2 (es)
CA (1)	CA2665692A1 (es)
CL (1)	CL2007002878A1 (es)
CO (1)	CO6180429A2 (es)
CR (1)	CR10759A (es)
EA (1)	EA200970353A1 (es)
EC (1)	ECSP099311A (es)
GE (1)	GEP20115218B (es)
IL (1)	IL197883A0 (es)
MA (1)	MA30815B1 (es)
MX (1)	MX2009003660A (es)
NO (1)	NO20091628L (es)
PE (1)	PE20080977A1 (es)
TN (1)	TN2009000119A1 (es)
TW (1)	TW200823218A (es)
WO (1)	WO2008044782A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1752457B1 (en) *	2004-06-02	2014-03-19	Takeda Pharmaceutical Company Limited	Fused heterocyclic compound
BRPI0813402A2 (pt)	2007-06-19	2014-12-30	Takeda Pharmaceutical	Agente para evitar ou tratar um câncer resistente a trastuzumab, droga combinada, métodos para prevenir ou tratar câncer resistente a trastuzumab, para examinar a sensibilidade de um câncer expressando her2 a um inibidor de her2, para tratar um câncer em um animal julgado ter baixa sensibilidade a um inibidor de her2 e para triar uma droga para a profilaxia ou tratamento de um câncer resistente a trastuzumab, e, uso de um ou mais medicamentos.
US8946239B2 (en) *	2008-07-10	2015-02-03	Duquesne University Of The Holy Spirit	Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof
WO2011040212A1 (en)	2009-10-01	2011-04-07	Takeda Pharmaceutical Company Limited	Therapeutic agent for brain tumor
KR101592258B1 (ko) *	2014-06-20	2016-02-05	보령제약 주식회사	제제 및 이의 제조방법
US20180045598A1 (en) *	2016-08-09	2018-02-15	Baker Hughes Incorporated	Subsea transition system
KR20220156862A (ko) *	2020-03-17	2022-11-28	마이크로벤션, 인코포레이티드	액체 색전제

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
YU33730B (en) *	1967-04-18	1978-02-28	Farmaceutici Italia	Process for preparing a novel antibiotic substance and salts thereof
JPS6019790A (ja) *	1983-07-14	1985-01-31	Yakult Honsha Co Ltd	新規なカンプトテシン誘導体
FR2601675B1 (fr) *	1986-07-17	1988-09-23	Rhone Poulenc Sante	Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
JP3040121B2 (ja) *	1988-01-12	2000-05-08	ジェネンテク，インコーポレイテッド	増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
US6136846A (en) *	1999-10-25	2000-10-24	Supergen, Inc.	Formulation for paclitaxel
JP2006500391A (ja) *	2002-09-04	2006-01-05	シェーリング　コーポレイション	サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
JP4366683B2 (ja)	2003-07-28	2009-11-18	武原力	熱サイホン
EP1752457B1 (en) *	2004-06-02	2014-03-19	Takeda Pharmaceutical Company Limited	Fused heterocyclic compound
CN1984656B (zh)	2004-06-04	2010-05-26	史密丝克莱恩比彻姆（科克）有限公司	癌症治疗药物
US7745446B2 (en) *	2004-09-06	2010-06-29	Bayer Schering Pharma Aktiengesellschaft	Pyrazolo[1,5-c]pyrimidines
JP2006275841A (ja)	2005-03-30	2006-10-12	Taiheiyo Cement Corp	セメント中のジエチレングリコール量の定量方法
JP2007057902A (ja)	2005-08-25	2007-03-08	Seiko Epson Corp	画像形成装置

2007
- 2007-10-05 US US12/444,309 patent/US20100008912A1/en not_active Abandoned
- 2007-10-05 MX MX2009003660A patent/MX2009003660A/es not_active Application Discontinuation
- 2007-10-05 CN CNA2007800453762A patent/CN101553222A/zh active Pending
- 2007-10-05 WO PCT/JP2007/070026 patent/WO2008044782A2/en not_active Ceased
- 2007-10-05 CA CA002665692A patent/CA2665692A1/en not_active Abandoned
- 2007-10-05 EP EP11156096A patent/EP2359825A2/en not_active Withdrawn
- 2007-10-05 TW TW096137401A patent/TW200823218A/zh unknown
- 2007-10-05 GE GEAP200711244A patent/GEP20115218B/en unknown
- 2007-10-05 BR BRPI0717477-2A patent/BRPI0717477A2/pt not_active IP Right Cessation
- 2007-10-05 PE PE2007001354A patent/PE20080977A1/es not_active Application Discontinuation
- 2007-10-05 JP JP2009514289A patent/JP2010505745A/ja not_active Abandoned
- 2007-10-05 CL CL200702878A patent/CL2007002878A1/es unknown
- 2007-10-05 EP EP07829761A patent/EP2063895A2/en not_active Withdrawn
- 2007-10-05 AU AU2007307489A patent/AU2007307489A1/en not_active Abandoned
- 2007-10-05 KR KR1020097009034A patent/KR20090094804A/ko not_active Withdrawn
- 2007-10-05 EA EA200970353A patent/EA200970353A1/ru unknown
- 2007-10-09 AR ARP070104424A patent/AR063152A1/es not_active Application Discontinuation
2009
- 2009-04-03 TN TNP2009000119A patent/TN2009000119A1/fr unknown
- 2009-04-05 IL IL197883A patent/IL197883A0/en unknown
- 2009-04-23 NO NO20091628A patent/NO20091628L/no not_active Application Discontinuation
- 2009-04-27 MA MA31822A patent/MA30815B1/fr unknown
- 2009-04-30 CR CR10759A patent/CR10759A/es unknown
- 2009-05-05 EC EC2009009311A patent/ECSP099311A/es unknown
- 2009-05-06 CO CO09045382A patent/CO6180429A2/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
TW200823218A (en)	2008-06-01
EP2359825A2 (en)	2011-08-24
MA30815B1 (fr)	2009-10-01
KR20090094804A (ko)	2009-09-08
JP2010505745A (ja)	2010-02-25
AU2007307489A1 (en)	2008-04-17
GEP20115218B (en)	2011-05-25
CO6180429A2 (es)	2010-07-19
NO20091628L (no)	2009-06-26
AR063152A1 (es)	2008-12-30
PE20080977A1 (es)	2008-09-05
CR10759A (es)	2009-05-27
WO2008044782A2 (en)	2008-04-17
WO2008044782A3 (en)	2008-12-11
TN2009000119A1 (en)	2010-10-18
EA200970353A1 (ru)	2009-10-30
IL197883A0 (en)	2009-12-24
MX2009003660A (es)	2009-04-22
BRPI0717477A2 (pt)	2015-06-16
EP2063895A2 (en)	2009-06-03
ECSP099311A (es)	2009-06-30
CN101553222A (zh)	2009-10-07
US20100008912A1 (en)	2010-01-14
CA2665692A1 (en)	2008-04-17

Similar Documents

Publication	Publication Date	Title
CL2007003523A1 (es)	2008-08-22	Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad de pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso en el tratamiento profilactico o terapeutico del cancer
CL2007003520A1 (es)	2008-08-22	Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
CL2008000377A1 (es)	2008-08-22	Compuestos derivados de ciclos fusionados sustituidos; agente farmaceutico que comprende a dichos compuestos; y uso para la prevencion o tratamiento de la diabetes.
CL2008001626A1 (es)	2009-06-05	Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer.
CL2007002261A1 (es)	2008-05-02	Compuestos derivados de imidazo[1,2-b]piridazina, inhibidores de quinasa; composicion farmaceutica; y uso en el tratamiento o prevencion del cancer.
DOP2012000290A (es)	2013-03-31	4-yodo-3-nitrobenzamida en combinacion con agentes anti-tumorales para el uso en el tratamiento de cancer utero y cancer de ovario
CL2007003138A1 (es)	2008-06-27	Compuestos derivados de anilinopiperazina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CL2007001724A1 (es)	2008-05-09	Uso de un estrogeno para el tratamiento de enfermedades, condiciones o sintomas asociados con niveles deficientes de estrogenos en una mujer; composicion farmaceutica que comprende unidades de dosificacion diarias de hemidrato de estradiol > 0,75 y 1
CL2008000254A1 (es)	2008-08-08	Compuestos derivados de 6-oxo-6,7-dihidro-5h-dibenzo-[b,d]azepin-7-ilo; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de la enfermedad de alzheimer o cancer.
CL2013001136A1 (es)	2014-03-07	Un agente inhibitorio de la fosfodiesterasa 7 (pde7) para ser usado en el tratamiento o la reduccion de la posibilidad de una adiccion; y composicion farmaceutica, forma de dosificacion unitaria y kit farmaceutico que incluyen al inhibidor de fosfodiesterasa 7 (pde7) y un agente terapeutico adicional.
CL2007003244A1 (es)	2008-04-04	Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CL2011000916A1 (es)	2011-09-16	Uso de una combinacion de un inhibidor de proteasoma epoxicetona peptidica o una sal farmaceutica aceptable del mismo, y uno o mas de otros agentes terapeuticos para tratar el cancer.
BRPI0815577A2 (pt)	2015-03-03	Peptídeo foxm1 e agente medicinal compreendendo o mesmo.
BRPI0717845A2 (pt)	2015-06-16	Uso de compostos, composições farmacêuticas e métodos para o tratamento e/ou profilaxia de enfermidades que podem ser tratadas com agentes de elevação de colesterol-hdl e compostos
CL2007002234A1 (es)	2008-06-13	Compuestos derivados de heterociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades proliferativas.
CL2007002878A1 (es)	2008-08-01	Agente farmaceutico que comprende 1) un inhibidor de her2 que tiene un esqueleto de pirrolopirimidina o de pirazolopirimidina y 2) un agente terapeutico hormonal o anticancerigeno en combinacion; y uso pra la prevencion o el tratamiento del cancer.
AR045179A1 (es)	2005-10-19	Uso de una combinacion de un inhibidor de la quinasa del receptor del factor de crecimiento epidermico y de agentes citotoxicos para el tratamiento e inhibicion del cancer
BRPI0720546A2 (pt)	2015-06-23	Composto, inibidor, medicamento, agente antitumor, composição farmacêutica, método para tratar câncer, e, uso do composto
CL2007002594A1 (es)	2008-06-06	Compuestos derivados de piridin-3-il, agentes inmunomoduladores; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de enfermedades asociadas con un sistema inmunologico activado. .
CL2008001076A1 (es)	2008-10-24	Compuestos derivados de sulfonamida; composicion farmaceutica; y uso en el tratamiento del cancer.
CL2011001536A1 (es)	2011-10-14	Compuestos derivados de pirimidin-2-il-1h-indol, inhibidores de la proteina quinasa atr; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos utiles para el tratamiento del cancer.
BRPI0815578A2 (pt)	2015-02-18	Peptídeo de cdca1 e agente farmacêutico compreendendo o mesmo.
CL2008001721A1 (es)	2008-12-19	Compuestos derivados de 17-beta-ciano-18 alfa-homo-19-nor-androst-4-eno; que presentan actividad gestagena y antimineralcorticoide; composicion farmaceutica; y uso en el tratamiento de trastornos pre-peri-y posmenopausicos y trastornos premenstruales.
CL2007002494A1 (es)	2008-04-04	Composicion farmaceutica que comprende una pirimidina trisustituida en combinacion con un compuesto con propiedades inhibitorias de pde5; y uso en el tratamiento de una enfermedad que involucre vasoconstriccion.
BRPI0816236A2 (pt)	2015-08-18	Peptídeo cdh3 e agente medicinal contendo o mesmo